FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Attorney Warns: FDA Watching Professional Promotion

[ Price : $8.95]

Attorney Nathan Downing says medical product companies should review their professional promotions as strictly as they review dire...

Patritumab BLA Pulled by Merck/Daiichi

[ Price : $8.95]

Merck and Daiichi Sankyo say they have withdrawn their BLA for the lung cancer drug patritumab deruxtecan.

Congressmen Hit FDA Covid Vaccine Limit

[ Price : $8.95]

Eight congressional Democrats call on FDA to eliminate its new limits on Covid-19 vaccines.

Drug Product Color Additive Replacement Guide

[ Price : $8.95]

FDA publishes a draft guidance with recommendations for replacing color additives in approved or marketed drug products.

Experimental Pancreatic Cancer Drug Gets Fast Track

[ Price : $8.95]

FDA grants the Experimental Drug Development Center a fast-track designation for EBC-129 and its use for treating pancreatic ducta...

Beam Gets Orphan Status for Genetic Disorder

[ Price : $8.95]

FDA grants Beam Therapeutics an orphan drug designation for BEAM-302, a liver-targeting lipid-nanoparticle that is designed to cor...

Multiple Issues at Germanys DRG Instruments

[ Price : $8.95]

FDA warns Marburg, Germany-based DRG Instruments that it is marketing diagnostic devices that do not have FDA approval and are bei...

House Democrats Want Answers on HHS Staff Cuts

[ Price : $8.95]

Complaining about a lack of information from the department, top Democrats on the House Energy and Commerce Committee ask HHS Secr...

FDA Publishes 2 Q-Submission Guidances

[ Price : $8.95]

FDA publishes two guidances relating to the CDRH/CBER Q-submission process.

GSK Plans for Antibiotic NDA in 2nd Half

[ Price : $8.95]

GSK plans to submit an NDA in the second half of the year after it and Spero Therapeutics announced that they will end their Phase...